<code id='8F0ED06ACA'></code><style id='8F0ED06ACA'></style>
    • <acronym id='8F0ED06ACA'></acronym>
      <center id='8F0ED06ACA'><center id='8F0ED06ACA'><tfoot id='8F0ED06ACA'></tfoot></center><abbr id='8F0ED06ACA'><dir id='8F0ED06ACA'><tfoot id='8F0ED06ACA'></tfoot><noframes id='8F0ED06ACA'>

    • <optgroup id='8F0ED06ACA'><strike id='8F0ED06ACA'><sup id='8F0ED06ACA'></sup></strike><code id='8F0ED06ACA'></code></optgroup>
        1. <b id='8F0ED06ACA'><label id='8F0ED06ACA'><select id='8F0ED06ACA'><dt id='8F0ED06ACA'><span id='8F0ED06ACA'></span></dt></select></label></b><u id='8F0ED06ACA'></u>
          <i id='8F0ED06ACA'><strike id='8F0ED06ACA'><tt id='8F0ED06ACA'><pre id='8F0ED06ACA'></pre></tt></strike></i>

          leisure time

          leisure time

          author:comprehensive    Page View:7717
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more
          Will the market for weight loss drugs really reach $100 billion?
          Will the market for weight loss drugs really reach $100 billion?

          DamianGardeofSTAT,left,talkedwithLiisaBaykoofEvercoreISIandJaredHolzofMizuhoabouttheGLP-1weightlossm

          read more
          Novavax promises a turnaround & Lilly roils the obesity market
          Novavax promises a turnaround & Lilly roils the obesity market

          SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We

          read more

          After half a century, Israel moves to evict squatter from his cave home on the beach

          A"welcomehome"blessingmadeofstonesitsatNissimKahlon'shomechiseledoutofthesandstonecliffsoverlookingt